molecule
MEET THE TEAM

Our management and operations teams have technical and business experience from across the chemicals industry. The board and management work closely with the operations group to deliver our strategy of building UK chemistry. The industry and academic leaders that permanently sit on our Science Advisory Group are supported by a rolling panel of customer representatives, who offer guidance on product value and synthesis strategy.

The Redbrick Molecular team are all dedicated to securing translation of academic research into attractive products that can positively impact the search for new therapeutic small molecules whilst enhancing the funding opportunities for university-led research.

ABOUT
MEET THE TEAM

Our management and operations teams have technical and business experience from across the chemicals industry. The board and management work closely with the operations group to deliver our strategy of building UK chemistry. The industry and academic leaders that permanently sit on our Science Advisory Group are supported by a rolling panel of customer representatives, who offer guidance on product value and synthesis strategy.

The Redbrick Molecular team are all dedicated to securing translation of academic research into attractive products that can positively impact the search for new therapeutic small molecules whilst enhancing the funding opportunities for university-led research.

blue_beaker
MANAGEMENT & OPERATIONS
  • Andy Hogben, CChem
    Andy Hogben, CChem MANAGING DIRECTOR

    Andy began his career as an industrial chemist where he developed patented distillation, biofuel and petrochemical processes through experiments at milligram-to-kilogram scale.

    Read More

    He then moved to the University of Sheffield to build new spin out businesses and manage the Faculty of Science intellectual property portfolio. Andy also leads the day-to-day operations of the company.

  • James Gibbons
    James Gibbons DIRECTOR

    James has a background in the pharmaceutical industry having held technical and commercial positions in a number of large and small pharma companies as well as contract research organisations.

    Read More

    After training as a pharmacologist and working in the neuropharmacology field, James moved into the commercial side of the pharmaceutical industry; leading a team responsible for technology commercialisation, marketing and BD&L at a leading drug delivery and formulation development company. He is now Senior IP & Commercialisation Manager at the University of Leeds where he identifies, protects, develops and commercialises University assets through licenses and spin-out companies.

  • Dan Cox, DPhil
    Dan Cox, DPhil CHEMIST

    Dan received his MChem from the University of Oxford and remained there to study his DPhil, researching novel methodologies in glycosylation chemistry.

    Read More

    After receiving his doctorate Dan joined the MRC Laboratory of Molecular Biology in Cambridge, working on developing new methodologies in the field of bioorthogonal chemistry. Dan subsequently moved to the University of Sheffield where he researched chemical methodologies designed to better understand the biosynthesis of bacterial cell walls as well as developing novel catalysts for phosphorylation reactions. Dan joined Redbrick Molecular as a synthetic organic chemist in June 2017.

  • Luke Watson, PhD
    Luke Watson, PhD BOARD OBSERVER

    Luke studied for his Masters degree in Chemistry at the University of Sheffield, followed by a PhD at the same institution, studying the tandem cyclisation/cycloaddition reactions of azomethine ylides under the supervision of Professor Iain Coldham.

    Read More

    After his studies, Luke went on to work in the technical side of industry where he worked on scale up of APIs and pharmaceutical intermediates before working for global agrichemical company, Syngenta, on large scale manufacture of agrichemicals. Luke now works in the Commercialisation team at the University of Leeds, where he works to identify and protect intellectual property arising in academic labs and seeks to commercialise this. He specialises in the fields of chemistry and engineering and physical sciences.

red_beaker
SCIENCE ADVISORY GROUP

Our Science Advisory Group provides scientific and technical advice to support the company in strategic decision making. The group discuss the latest academic and industrial developments in organic and medicinal chemistry and report to our company board.

The group comprises permanent advisors from industry and academia but is also supported by leaders from our core customers who attend as guests to enhance the collaborative relationships between our companies.

  • Professor Adam Nelson, FRSC
    Professor Adam Nelson, FRSC PERMANENT ACADEMIC MEMBER

    Adam is Professor of Chemical Biology at the University of Leeds where he leads a buoyant group that exploits synthetic chemistry to address challenges in biology and drug discovery.

    Read More

    He leads the review and selection of EU chemistry for translation into innovative compound libraries within the €196M European Lead Factory (2013-17).  He is currently an EPSRC Established Career Fellow (2016-21) and an investigator on PoPPI, an EPSRC programme grant focused on the modulation of protein-protein interactions (2016-21).

  • Professor Simon Jones, CChem, FRSC
    Professor Simon Jones, CChem, FRSC PERMANENT ACADEMIC MEMBER

    Simon is an academic member of staff of the University of Sheffield specialising in synthetic organic chemistry, with research interests in asymmetric synthesis and catalysis.

    Read More

    He is involved in several collaborative research projects, particularly looking at antimicrobial targets. Simon is also currently Faculty Director for External Relations with the Faculty of Science, responsible for engaging with external stakeholders locally, nationally and internationally.

  • David Lathbury, PhD, FRSC
    David Lathbury, PhD, FRSC CHAIRMAN

    David began his career at Shell, followed by a series of process development roles in the pharmaceutical and fine chemicals sector. He is now an independent consultant advising a series of customers on all aspects of chemical process development.

Start typing and press Enter to search